United States Biotechnology & Medical Research

Maze Therapeutics Inc (MAZE)

Track

Over the past 90 days, Maze Therapeutics Inc. insiders have executed 28 transactions, all of which were sales totaling approximately $10.44 million. Key executives, including CEO Jason V. Coloma and President Harold Bernstein, have consistently utilized planned and proposed sales. These activities follow the company's May 2026 results financiers, which showed an earnings beat.
Ticker: MAZE Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Maze Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 3 Aug 2026
Value US$3,668,982.47 | Price 223.55 | Shares 60,035 (-36.1%)
Planned sale 3 Aug 2026
Value US$1,143,187.43 | Price 241.15 | Shares 76,468 (-31.6%)
Planned sale 3 Aug 2026
Value US$100,000.00 | Price 27.09 | Shares 1,000 (-0.7%)
Planned sale 3 Aug 2026
Value US$100,000.00 | Price 26.71 | Shares 1,000 (-10.5%)
Proposed sale 3 Aug 2026
Value US$100,000.00 | Price 26.74 | Shares 1,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-05 2026-08-03 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
60,035 -36.1%
223.55
US$3,668,982 		60,035 -36.1% 223.55 US$3,668,982
2026-08-05 2026-08-03 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
76,468 -31.6%
241.15
US$1,143,187 		76,468 -31.6% 241.15 US$1,143,187
2026-08-05 2026-08-03 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
35,879 +41.1%
380.23
US$1,492,811 		35,879 +41.1% 380.23 US$1,492,811
2026-08-05 2026-08-03 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
1,000 -10.5%
26.71
US$100,000 		1,000 -10.5% 26.71 US$100,000
2026-08-03 2026-08-03 PrS Proposed sale
Coloma Jason V

Officer

Officer
1,000
26.74
US$100,000 		1,000 26.74 US$100,000
2026-07-31 2026-07-29 PlS Planned sale
Dandekar Atul

CSBO

Officer
1,000 -1.5%
27.89
US$100,000 		1,000 -1.5% 27.89 US$100,000
2026-07-31 2026-07-29 PlS Planned sale
Dandekar Atul

CSBO

Officer
1,000 -21.0%
27.31
US$100,000 		1,000 -21.0% 27.31 US$100,000
2026-07-29 2026-07-29 PrS Proposed sale
ATUL DANDEKAR

Officer

Officer
1,000
27.88
US$100,000 		1,000 27.88 US$100,000
2026-07-02 2026-07-01 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
1,200 -100.0%
30.34
US$36,404 		1,200 -100.0% 30.34 US$36,404
2026-07-02 2026-07-01 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
13,409 -91.8%
29.87
US$400,460 		13,409 -91.8% 29.87 US$400,460
2026-07-02 2026-07-01 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
1,597 -0.6%
30.44
US$48,606 		1,597 -0.6% 30.44 US$48,606
2026-07-02 2026-07-01 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
30,311 -9.5%
29.95
US$907,921 		30,311 -9.5% 29.95 US$907,921
2026-07-02 2026-07-01 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
2,593 -10.0%
29.98
US$77,726 		2,593 -10.0% 29.98 US$77,726
2026-07-01 2026-07-01 PrS Proposed sale
HAROLD BERNSTEIN

Officer

Officer
46,892
29.84
US$1,399,257 		46,892 29.84 US$1,399,257
2026-07-01 2026-07-01 PrS Proposed sale
Coloma Jason V

Officer

Officer
34,501
29.98
US$1,034,254 		34,501 29.98 US$1,034,254
2026-07-01 2026-06-29 PlS Planned sale
Dandekar Atul

CSBO

Officer
7,500 -22.2%
28.02
US$210,150 		7,500 -22.2% 28.02 US$210,150
2026-06-24 2026-06-23 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
23,865 -7.0%
26.05
US$621,674 		23,865 -7.0% 26.05 US$621,674
2026-06-24 2026-06-22 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
2,040 -7.3%
26.00
US$53,040 		2,040 -7.3% 26.00 US$53,040
2026-06-24 2026-06-22 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
1,953 -0.6%
26.00
US$50,781 		1,953 -0.6% 26.00 US$50,781
2026-06-03 2026-06-01 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
1,600 -100.0%
26.36
US$42,172 		1,600 -100.0% 26.36 US$42,172
2026-06-03 2026-06-01 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
13,253 -89.2%
25.57
US$338,940 		13,253 -89.2% 25.57 US$338,940
2026-06-03 2026-06-01 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
553 -1.9%
26.24
US$14,511 		553 -1.9% 26.24 US$14,511
2026-06-03 2026-06-01 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
6,090 -1.7%
26.20
US$159,537 		6,090 -1.7% 26.20 US$159,537
2026-06-01 2026-06-01 PrS Proposed sale
Coloma Jason V

Officer

Officer
34,501
26.32
US$908,066 		34,501 26.32 US$908,066
2026-06-02 2026-05-29 PlS Planned sale
Dandekar Atul

CSBO

Officer
7,500 -23.2%
26.34
US$197,554 		7,500 -23.2% 26.34 US$197,554
2026-05-27 2026-05-26 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
25,582 -6.8%
26.02
US$665,516 		25,582 -6.8% 26.02 US$665,516
2026-05-27 2026-05-22 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
2,478 -8.0%
26.00
US$64,428 		2,478 -8.0% 26.00 US$64,428
2026-05-27 2026-05-22 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
4,504 -1.2%
26.00
US$117,104 		4,504 -1.2% 26.00 US$117,104
2026-05-18 2026-05-15 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
116 -0.4%
26.00
US$3,016 		116 -0.4% 26.00 US$3,016
2026-05-18 2026-05-15 PlS Planned sale
Coloma Jason V

Chief Executive Officer

Executive Director
1,822 -0.5%
26.00
US$47,372 		1,822 -0.5% 26.00 US$47,372
2026-05-15 2026-05-15 PrS Proposed sale
Coloma Jason V

Officer

Officer
34,502
25.95
US$895,327 		34,502 25.95 US$895,327
2026-05-18 2026-05-14 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
15,000 -100.0%
26.22
US$393,354 		15,000 -100.0% 26.22 US$393,354
2026-05-01 2026-04-29 PlS Planned sale
Dandekar Atul

CSBO

Officer
7,500 -41.7%
25.37
US$190,299 		7,500 -41.7% 25.37 US$190,299
2026-04-02 2026-04-01 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
300 -2.3%
30.34
US$9,101 		300 -2.3% 30.34 US$9,101
2026-04-02 2026-04-01 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
300 -2.3%
30.34
US$9,101 		300 -2.3% 30.34 US$9,101
2026-04-02 2026-04-01 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
2,200 -14.2%
29.32
US$64,510 		2,200 -14.2% 29.32 US$64,510
2026-04-02 2026-04-01 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
2,200 -14.2%
29.32
US$64,510 		2,200 -14.2% 29.32 US$64,510
2026-04-02 2026-04-01 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
300 -100.0%
31.07
US$9,320 		300 -100.0% 31.07 US$9,320
2026-04-02 2026-04-01 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
3,348 -91.8%
30.06
US$100,636 		3,348 -91.8% 30.06 US$100,636
2026-04-02 2026-04-01 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
11,352 -75.7%
29.24
US$331,948 		11,352 -75.7% 29.24 US$331,948
2026-04-01 2026-03-30 PlS Planned sale
Dandekar Atul

CSBO

Officer
790 -7.0%
30.02
US$23,714 		790 -7.0% 30.02 US$23,714
2026-04-01 2026-03-30 PlS Planned sale
Dandekar Atul

CSBO

Officer
6,710 -37.3%
29.26
US$196,305 		6,710 -37.3% 29.26 US$196,305
2026-03-30 2026-03-30 PrS Proposed sale
ATUL DANDEKAR

Officer

Officer
30,000
30.38
US$911,400 		30,000 30.38 US$911,400
2026-03-20 2026-03-20 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
5,044 -100.0%
50.02
US$252,294 		5,044 -100.0% 50.02 US$252,294
2026-03-20 2026-03-20 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
3,795 -42.9%
49.32
US$187,169 		3,795 -42.9% 49.32 US$187,169
2026-03-20 2026-03-20 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
6,161 -41.1%
48.20
US$296,977 		6,161 -41.1% 48.20 US$296,977
2026-03-12 2026-03-10 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
348 -100.0%
51.02
US$17,753 		348 -100.0% 51.02 US$17,753
2026-03-12 2026-03-10 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
29,652 -98.8%
50.45
US$1,495,807 		29,652 -98.8% 50.45 US$1,495,807
2026-03-10 2026-03-10 PrS Proposed sale
HAROLD BERNSTEIN

Officer

Officer
74,853
45.06
US$3,372,876 		74,853 45.06 US$3,372,876
2026-03-03 2026-03-02 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
3,700 -22.2%
45.47
US$168,237 		3,700 -22.2% 45.47 US$168,237
2026-03-03 2026-03-02 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
1,300 -7.2%
44.44
US$57,774 		1,300 -7.2% 44.44 US$57,774
2026-03-03 2026-02-27 PlS Planned sale
Dandekar Atul

CSBO

Officer
3,761 -26.4%
45.72
US$171,967 		3,761 -26.4% 45.72 US$171,967
2026-03-03 2026-02-27 PlS Planned sale
Dandekar Atul

CSBO

Officer
3,739 -20.8%
45.13
US$168,756 		3,739 -20.8% 45.13 US$168,756
2026-02-04 2026-02-02 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
736 -5.4%
46.63
US$34,321 		736 -5.4% 46.63 US$34,321
2026-02-04 2026-02-02 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
4,064 -22.9%
46.03
US$187,068 		4,064 -22.9% 46.03 US$187,068
2026-02-04 2026-02-02 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
200 -1.1%
44.15
US$8,830 		200 -1.1% 44.15 US$8,830
2026-02-04 2026-02-02 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
100 -100.0%
47.23
US$4,723 		100 -100.0% 47.23 US$4,723
2026-02-04 2026-02-02 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
5,936 -98.3%
46.37
US$275,271 		5,936 -98.3% 46.37 US$275,271
2026-02-04 2026-02-02 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
8,364 -58.1%
45.89
US$383,816 		8,364 -58.1% 45.89 US$383,816
2026-02-04 2026-02-02 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
600 -4.0%
44.21
US$26,523 		600 -4.0% 44.21 US$26,523
2026-02-04 2026-02-02 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
736 -5.4%
46.63
US$34,321 		736 -5.4% 46.63 US$34,321
2026-02-04 2026-02-02 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
4,064 -22.9%
46.03
US$187,068 		4,064 -22.9% 46.03 US$187,068
2026-02-04 2026-02-02 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
200 -1.1%
44.15
US$8,830 		200 -1.1% 44.15 US$8,830
2026-02-04 2026-02-02 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
100 -100.0%
47.23
US$4,723 		100 -100.0% 47.23 US$4,723
2026-02-04 2026-02-02 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
5,936 -98.3%
46.37
US$275,271 		5,936 -98.3% 46.37 US$275,271
2026-02-04 2026-02-02 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
8,364 -58.1%
45.89
US$383,816 		8,364 -58.1% 45.89 US$383,816
2026-02-04 2026-02-02 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
600 -4.0%
44.21
US$26,523 		600 -4.0% 44.21 US$26,523
2026-02-02 2026-01-29 PlS Planned sale
Dandekar Atul

CSBO

Officer
2,800 -21.0%
45.01
US$126,022 		2,800 -21.0% 45.01 US$126,022
2026-02-02 2026-01-29 PlS Planned sale
Dandekar Atul

CSBO

Officer
3,500 -20.8%
44.04
US$154,147 		3,500 -20.8% 44.04 US$154,147
2026-02-02 2026-01-29 PlS Planned sale
Dandekar Atul

CSBO

Officer
1,200 -6.7%
43.18
US$51,821 		1,200 -6.7% 43.18 US$51,821
2026-01-26 2026-01-22 PlS Planned sale
Bachrodt Amy

SVP, Finance

Officer
5,000 -27.8%
45.52
US$227,612 		5,000 -27.8% 45.52 US$227,612
2026-01-16 2026-01-16 PrS Proposed sale
SEKAR KATHIRESAN

Former Director

Non-Executive Director
29,772
40.67
US$1,210,937 		29,772 40.67 US$1,210,937
2026-01-09 2026-01-07 PlS Planned sale
Bernstein Harold

President, R&D & CMO

Officer
25,156 -100.0%
40.20
US$1,011,299 		25,156 -100.0% 40.20 US$1,011,299
2026-01-08 2026-01-07 S Sale
3.2
Sohn Catherine A.
Non-Executive Director
26,920 -100.0%
39.11
US$1,052,785 		26,920 -100.0% 39.11 US$1,052,785
2026-01-07 2026-01-07 PrS Proposed sale
3.2
CATHERINE SOHN

Director

Non-Executive Director
26,920
39.11
US$1,052,785 		26,920 39.11 US$1,052,785
Explore more

More insider trading research around Maze Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America